Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

100564-78-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

100564-78-1 Usage


Boc-L-homophenylalanine, also known as N-Boc-L-homophenylalanine, is a white powder with specific chemical properties. It is a derivative of the naturally occurring amino acid L-homophenylalanine, featuring a Boc (tert-butyloxycarbonyl) protecting group attached to the amino group. This modification enhances its stability and reactivity in various chemical processes, making it a valuable compound in the field of organic synthesis.


Used in Organic Synthesis:
Boc-L-homophenylalanine is used as a reagent in organic synthesis for its ability to participate in a wide range of chemical reactions. The presence of the Boc group allows for selective protection and deprotection steps, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Boc-L-homophenylalanine is used as a building block for the development of novel drugs. Its unique structure and reactivity contribute to the design and synthesis of new pharmaceutical compounds with potential therapeutic applications.
Used in the Preparation of Proteasome Inhibitors:
Specifically, Boc-L-homophenylalanine is utilized in the synthesis of piperidine-containing peptidyl proteasome inhibitors. These inhibitors are of significant interest due to their potential as therapeutic agents in the treatment of various diseases, including cancer and neurodegenerative disorders. The incorporation of Boc-L-homophenylalanine into these inhibitors allows for the exploration of structure-activity relationships and the optimization of their pharmacological properties.

Check Digit Verification of cas no

The CAS Registry Mumber 100564-78-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,5,6 and 4 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 100564-78:
91 % 10 = 1
So 100564-78-1 is a valid CAS Registry Number.

100564-78-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (B4356)  N-(tert-Butoxycarbonyl)-L-homophenylalanine  >98.0%(HPLC)(T)

  • 100564-78-1

  • 1g

  • 350.00CNY

  • Detail
  • TCI America

  • (B4356)  N-(tert-Butoxycarbonyl)-L-homophenylalanine  >98.0%(HPLC)(T)

  • 100564-78-1

  • 5g

  • 1,200.00CNY

  • Detail
  • Alfa Aesar

  • (H51966)  (S)-2-(Boc-amino)-4-phenylbutyric acid, 98%   

  • 100564-78-1

  • 1g

  • 849.0CNY

  • Detail
  • Alfa Aesar

  • (H51966)  (S)-2-(Boc-amino)-4-phenylbutyric acid, 98%   

  • 100564-78-1

  • 5g

  • 3334.0CNY

  • Detail
  • Aldrich

  • (15469)  Boc-Homophe-OH  ≥98.0% (TLC)

  • 100564-78-1

  • 15469-1G

  • 731.25CNY

  • Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017


1.1 GHS Product identifier

Product name (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid

1.2 Other means of identification

Product number -
Other names Boc-L-homophenylalanine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:100564-78-1 SDS

100564-78-1Relevant articles and documents

Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors

Schirmeister, Tanja,Kesselring, Jochen,Jung, Sascha,Schneider, Thomas H.,Weickert, Anastasia,Becker, Johannes,Lee, Wook,Bamberger, Denise,Wich, Peter R.,Distler, Ute,Tenzer, Stefan,Johé, Patrick,Hellmich, Ute A.,Engels, Bernd

, p. 8332 - 8335 (2016)

We propose a structure-based protocol for the development of customized covalent inhibitors. Starting from a known inhibitor, in the first and second steps appropriate substituents of the warhead are selected on the basis of quantum mechanical (QM) computations and hybrid approaches combining QM with molecular mechanics (QM/MM). In the third step the recognition unit is optimized using docking approaches for the noncovalent complex. These predictions are finally verified by QM/MM or molecular dynamic simulations. The applicability of our approach is successfully demonstrated by the design of reversible covalent vinylsulfone-based inhibitors for rhodesain. The examples show that our approach is sufficiently accurate to identify compounds with the desired properties but also to exclude nonpromising ones.

Synthetic Elaboration of the Side Chain of (R)-2,2-Dimethyl-3-(tert-butoxycarbonyl)-4-ethynyloxazolidine: A New Regio- And Stereoselective Strategy to δ-Functionalized β-Amino Alcohols

Reginato, Gianna,Mordini, Alessandro,Caracciolo, Massimo

, p. 6187 - 6192 (1997)

An investigation of the reactivity of ethynyloxazolidine 2 is presented. Functionalization at the acetylenic position has been found to occur very easily using the mild Sonogashira conditions. Addition of tributyltin cuprate 1 provided the corresponding stannylated (E)-ethenyloxazolidine 3, a new chiral building block which has been reacted with electrophiles under Pd catalysis. The reaction sequence occurred without racemization and showed an easy and mild procedure for the regio- and stereoselective synthesis of unsaturated amino alcohols.



Paragraph 0456, (2016/10/08)

The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation

Ettari, Roberta,Pinto, Andrea,Previti, Santo,Tamborini, Lucia,Angelo, Ilenia C.,La Pietra, Valeria,Marinelli, Luciana,Novellino, Ettore,Schirmeister, Tanja,Zappalà, Maria,Grasso, Silvana,De Micheli, Carlo,Conti, Paola

, p. 7053 - 7060 (2015/11/11)

Novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation were developed; some of them possess Ki values in the micromolar range. We studied the structure-activity relationship of these derivatives and we performed docking studies, which allowed us to find out the key interactions established by the inhibitors with the target enzyme. Biological results indicate that the nature of the P2 and P3 substituents and their binding to the S2/S3 pockets is strictly interdependent.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 100564-78-1